1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 27 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2012Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine ABlake, S.; Hughes, T.; Lyons, A.
2006Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib eraGrigg, A.; Hughes, T.
2010Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cellsEadie, L.; Hughes, T.; White, D.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
2011OCT-1 as a determinant of response to antileukemic treatmentEngler, J.; Hughes, T.; White, D.
2011Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialKantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
2009Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapyHughes, T.; Hochhaus, A.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.

Discover